Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6

I'm hearing whispers ,, we may not be about to have a CR ,, CHM may well be a Buy/out target ..and the buyer doesn't require CHM to have any cash or staff in the transaction..

. One patient achieved a complete response which has been sustained for over 48 months and is alive today.
The Phase 1B study (NCT05400122) is intended to build upon the clinical responses seen in the initial CHM
CORE-NK Phase 1A clinical trial by adding vactosertib, an oral TGF-β receptor inhibitor that can
potentially disrupt the TGF-β signaling pathway